Stock LONN LONZA GROUP AG
Add to a list

ETFs Lonza Group AG

Stocks

LONN

CH0013841017

Biotechnology & Medical Research

Market Closed - Swiss Exchange
Other stock markets
 09:01:48 14/07/2026 pm IST 		5-day change 1st Jan Change
582.40 CHF -1.05% Intraday chart for Lonza Group AG +1.39% +8.29%
14/07 Swiss Market Index Slips; Roche Shares Down MT
14/07 Where would AI lead Pharma in the long run? Alphavalue

ETFs positioned on Lonza Group AG

Name YTD change Weight AuM
LYXOR DJ SWITZERLAND TITANS 30 (DR) UCITS ETF- CHF ETF Lyxor DJ Switzerland Titans 30 (DR) UCITS ETF- CHF
-.--%3.83% 121 M€
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY ETF Nomura NEXT FUNDS International Equity MSCI-KOKUSAI (Yen-Hedged) ETF - JPY
+7.64%1.77% 27 M€
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS - VANGUARD FTSE ALL-WORLD EX-US ETF ETF Vanguard International Equity Index Funds - Vanguard FTSE All-World ex-US ETF
+7.60%0.18% 33,076 M€
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (UNHEDGED) ETF - JPY ETF Nomura NEXT FUNDS International Equity MSCI-KOKUSAI (Unhedged) ETF - JPY
+13.24%0.08% 426 M€
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF - DISTRIBUTING - EUR ETF Vanguard LifeStrategy 40% Equity UCITS ETF - Distributing - EUR
+3.56%0.03% 37 M€
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF - DISTRIBUTING - EUR ETF Vanguard LifeStrategy 20% Equity UCITS ETF - Distributing - EUR
+0.29%0.01% 15 M€
CI MARRET ALTERNATIVE ABSOLUTE RETURN BOND ETF - CAD ETF CI Marret Alternative Absolute Return Bond ETF - CAD
0.00%-0% 12 M€
12

Company Profile

Logo Lonza Group AG
Lonza Group AG is one of the world leaders of the contract development and manufacturing of pharmaceutical and biotechnology products. Net sales break down by family of products and services as follows: - biologics and bio-pharmaceuticals (55.9%): microbiological fermentation products, mammalian cell-based bio-pharmaceuticals, monoclonal antibodies, therapeutic proteins, etc.; - synthesis products (24.7%): chemopharmaceutical products, bioconjugates, small molecules, active pharmaceutical ingredients, complex intermediates, etc.; - specialised therapeutic products (15.8%): cell and gene therapies, synthetic therapeutic nucleic acids, oligonucleotides, microbial biological products, etc.; - others (3.6%).
Employees
20,000
Sector
Biotechnology & Medical Research
Calendar
22/07 - Earnings release - Q2 2026
More about the company

Income Statement and Estimates

More financial data

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.

Quality

Quality

This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

ESG MSCI

ESG MSCI

The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

AAA
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
582.40CHF
Average target price
669.22CHF
Spread / Average Target
+14.91%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Stocks
  3. LONN Stock
  4. ETFs Lonza Group AG

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition